AbbVie Inc

ABBV is in a Stage 2 advance backed by a high-conviction Momentum Breakout, confirming demand overwhelming prior supply. However, price is extended above the rising 9/21 EMAs and tagged overbought, warranting caution. The medium-term bias remains bullish on intact higher highs/lows and dynamic EMA support. Short-term timing is neutral; we will stalk a shallow pullback into the 9/21 EMA zone before engaging under the Growth at Reasonable Price framework.

• ↑Q1 adjusted EPS of $2.65 beat guidance by $0.07 on 12.4% YoY revenue growth to $15 billion.
• ↑Skyrizzy commands over 45% psoriasis market share, boosting immunology revenues.
• ↓Humira revenues plunged 40.3% YoY after biosimilar launches, eroding cash flow.